Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer
This trial is active, not recruiting.
|Treatments||soy isoflavones, soy protein isolate, placebo|
|Sponsor||Comprehensive Cancer Center of Wake Forest University|
|Collaborator||National Cancer Institute (NCI)|
|Start date||October 2003|
|End date||July 2006|
|Trial size||62 participants|
|Trial identifier||NCT00345813, CCCWFU-98203, CCCWFU-BG03-332, CDR0000466317|
RATIONALE: Dietary supplementation with soy may keep prostate cancer from growing in patients planning to undergo surgery.
PURPOSE: This randomized phase II trial is studying a soy supplement to see how well it works compared to a placebo in treating patients undergoing surgery for localized prostate cancer.
|Endpoint classification||pharmacokinetics/dynamics study|
|Intervention model||parallel assignment|
|Masking||double blind (subject, caregiver, investigator, outcomes assessor)|
Correlation of pretreatment ER-β expression with response to soy supplementation
time frame: within 21 days after completetion of supplement regimen
Male participants at least 18 years old.
DISEASE CHARACTERISTICS: - Histologically confirmed adenocarcinoma of the prostate - Clinically localized disease - Scheduled for radical prostatectomy - No evidence of metastatic disease by bone scan or CT scan of the abdomen or pelvis PATIENT CHARACTERISTICS: - ECOG performance status 0-2 - No evidence of active nephrolithiasis - No history of hypercalcemic syndrome PRIOR CONCURRENT THERAPY: - No prior treatment for prostate cancer, including radiotherapy, systemic chemotherapy, surgery, or investigational drugs - No other concurrent dietary supplementation with soy, cholecalciferol (vitamin D), or fish oil
|Official title||Randomized Phase IIb Preprostatectomy Study of Dietary Supplementation With Soy and Biomarkers of Prostate Cancer Risk and Progression|
|Description||OBJECTIVES: Primary - Compare the effect of dietary supplementation with soy vs placebo on biomarkers of cell cycle regulation, proliferation, differentiation, apoptosis, and signaling pathways in patients with localized prostate cancer scheduled to undergo radical prostatectomy. Secondary - Compare the toxicity and side effects of these regimens in these patients. - Compare the dietary patterns of these patients. OUTLINE: This is a prospective, randomized study. Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive oral soy supplementation daily for 4 weeks. - Arm II: Patients receive oral placebo supplementation daily for 4 weeks. Patients undergo radical prostatectomy within 21 days after completion of soy or placebo supplementation. Blood and tissue samples are collected for biomarker analysis using immunohistochemistry.|
Call for more information